Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Tempest Therapeutics(TPST.US)$ Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications 2 MINUTES AGO, 8:00 AM EDT VIA GLOBENEWSWIRE TPST    TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers Based on subsequent positive randomized data, Company preparing to move TPST-1120 into pivotal Phase 3 trial in HCC
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
+0
5
Translate
Report
4449 Views
Comment
Sign in to post a comment
1778Followers
29Following
21KVisitors
Follow